This compound has shown efficacy at well tolerated doses in NSCLC patients in patients with amplified or mutated c-Met, and in those with ALK abnormalities, but had little activity in NSCLC without these abnormalities [8]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.